For advanced HR+/HER2- breast cancer, the combination of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) with endocrine therapy has become the established first-line standard, significantly prolonging both median progression-free survival (mPFS) and overall survival (OS). The gene discussed is ERBB2; the disease is breast cancer.